GVV858

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Advanced CCNE1-amplified Solid TumorsAdvanced HR+/HER- breast cancerAdvanced HR+/HER2- Breast CancerMetastatic Castration-resistant Prostate Cancer

Phase 1

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

RecruitingNCT07288359

Novartis PharmaceuticalsAdvanced CCNE1-amplified Solid Tumors, Advanced HR+/HER2- Breast Cancer, Metastatic Castration-resistant Prostate Cancer

Start: 2025-12-29End: 2031-05-09Target: 205Updated: 2026-07-30

An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors

Not yet recruitingCTIS2025-521911-38-00

Novartis Pharma AGAdvanced HR+/HER- breast cancer

Target: 26Updated: 2026-04-17